ABSTRACT AIM: To study the development of children with selectively treated cytomegalovirus infection. PATIENTS AND METHODS: We studied prospectively a risk group of 12 children with cytomegalovirus infection. These children were diagnosed by serological screening in the fi rst three months after birth and are defi ned as congenital and perinatal infections. Thirteen infants with no serological evidence of previous or present cytomegalovirus infection at 4 -12 months of age were used as controls. Ganciclovir in a dose of 10-15 mg/kg/day for at least 2 weeks followed by 5-7.5 mg/kg/day administered intravenously for at least 2 weeks more was given to 4 children from the risk group with PCR confi rmed cytomegalovirus infection: to one with suspected congenital infection that presented with encephalitis, to two children with abnormal auditory evoked potentials (AEPs) and other non-neurological symptoms of a suspected congenital infection, and to one child with proven congenital infection with systemic manifestations. There was no infant with cytomegalic inclusion disease in the study. All other children in the risk group that had clinically manifested infection received isoprinosine in a dose of 50 mg/kg for one month. RESULTS: Psychomotor development delay at age three was found in two children from the risk group and in one child in the control group. There was no difference between the two groups regarding the frequency of paroxysmal events, sensory defi ciency or frequent illnesses. CONCLUSIONS: The prognosis in cases of cytomegalovirus infection diagnosed at three years of age and treated selectively can be similar to that in infection free 3-year-old children (if there are no cases of CMV inclusion disease).
INTRODUCTION
Cytomegalovirus infection (CMV) is among the most common infections developed during the fi rst year of life with manifestations varying in type and severity. [1] [2] [3] [4] Symptomatic congenital CMV infection may cause delayed psychomotor development, sensorineural hearing loss and other pathological conditions in 70-95% of the patients that have survived it, while these same disorders caused by the asymptomatic type of infection have an incidence of only 5-25%. 1, 5, 6 Symptomatic CMV infection may also cause neurological sequelae with/without mental retardation in premature infants and in fullterm neonates with other diseases, although it is unclear how frequent this could be. 1 Prognostically, the treated CMV infection is insuffi ciently studied, the attention being drawn only to the rare cases of congenital infection with severe neurological sequelae. 7, 8 Treatment with ganciclovir (GCV) applied to these children reduces the frequency of hearing impairment at age one year from 68% to 21%. 7 Normal psychomotor development (PMD) at 2 years of age is established in 24% of the treated patients (R Whitley et al. the central nervous system 5, 7, 9 and/or in cases of severe clinical course of the disease 5 . When the infection is acquired after the neonatal period immunomodulators are recommended or spontaneous healing is expected. 1, 8 The aim of the present paper was to study the development of children with selectively treated congenital and perinatal CMV infection.
MATERIAL AND METHODS
Design of the study: open three-year cohort controlcase epidemiological study of a series of cases of CMV infection (Fig. 1) . Serological diagnosis of CMV infection: qualitative determination of CMV IgM and quantitative determination of CMV IgM in IU/ml (EIA-1796 and EIA-1797, DRG International Inc., USA). In CMV IgM negative -CMV IgG positive children at 3 to 6 months of age we also studied the mothers' CMV IgG, and for children with the same CMV serology up to 3 months old we repeated the test for CMV IgG one to two months after baseline. 4 -concomitant infection -if there are symptoms characteristic of CMV infection, but there are also other etiologic factors that may account for these symptoms (e.g., hypoxic-ischemic encephalopathy).
-asymptomatic infection -if the infection is diagnosed in a child without symptoms of CMV infection hospitalized for other reasons (e.g., in a child with obstetric brachial plexus palsy). 1, 6 CLASSIFICATION ACCORDING TO THE TIME OF INFECTION WITH CMV -certain congenital infection -when the infection is detected within 21 days of age.
-probable congenital infection -in clinical manifestation of CMV infection in the neonatal period, but it is confi rmed after 21 days of age.
-unknown -when it cannot be classifi ed as congenital. 6 Therapeutic algorithm for CMV infection: GCV was administered only after parental consent was obtained to children with CMV infection confi rmed by PCR, aged 0-119 days with neurological symptoms (combinations of changes in consciousness, muscle tone, refl exes, seizures, cerebrospinal fl uid hyperproteinorachy and/or pleocytosis, increased immunoglobulins in the cerebrospinal fl uid, pronounced lenticulostriate vasculitis seen in trasfontanellar ultrasonography, cerebral calcifi cations, microcephaly) and/or abnormal auditory evoked potentials and/or severe polysystemic clinical manifestation. GCV was administered intravenously in a dose of 10 mg/kg/ day in two applications (and as much as 15 mg/ kg/day if there were neurological symptoms) for at least two weeks, then the patients were started on a maintaining regimen: the drug was given in a dose of 5-7.5 mg/kg daily for at least another two weeks. 2, 8 Infected children without indications for GCV treatment received the immunomodulator isoprinosine (Inosine pranobex) (50 mg/kg daily per os) for at least 1 month.
The groups were formed based on the risk for sequelae: a risk group -the children in this group had the CMV infection diagnosed within 119 days after birth. The age groups were chosen so that they could include all children with congenital and perinatal infections, given the incubation period is 1 to 3 mo. 6 Control group -the children included in this group displayed no serologic evidence for past or present CMV infection when examined between 4 and 12 months of age.
Follow-up study: all children found to have a symptomatic CMV infection in the fi rst 4 mo of life were followed clinically and biochemically throughout the fi rst year and their auditory evoked potentials were measured at 12 months.
Developmental assessment at 3 years for the risk and control groups included clinical examination and interviews with parents and/or the family physicians. We developed a special questionnaire that included questions about the health status of the child at a particular time, the basic psychomotor development components, information about any paroxysmal, sensory and/or other pathology, type and frequency rate of intercurrent illnesses ( Table 2) .
Analysis of the data for the development at 3 years of age: The responses to the questions on psychomotor development were analyzed qualitatively (number of cases in each group that do not fulfi l the respective criteria) and quantitatively (mean age at which the respective criteria were fi rst fulfi lled). The questionnaire item "shows a delay in the psychomotor development" in the parents' assessment was reviewed by a paediatric neurologist by comparing the data about the achievements in individual components of psychomotor development with relevant reference values. The remainder of the questions in the survey not concerning the psychomotor development were assessed qualitatively. Frequent morbidity was defi ned as having more than 6 morbid events per year for at least 1 year until the child becomes 3 years of age.
Statistical analysis included the analysis of 
RESULTS
Of the 169 hospitalized children in the study sample 6 were excluded: 5 for absent serologic examinations for СМV and 1 because of parental refusal, leaving a total number of 163 children (Fig. 1) . Fifty-four children had a CMV infection, 8 children had a suspected CMV infection and 101 children were infection-free. The children were allocated into two groups: a risk group including 22 children and a control group of 31 children. Ten children of the risk group were lost to the follow-up study until the age of 3 leaving 12 for subsequent assessment.
In the control group 9 children were lost to the follow-up. Of the remaining 22 children, 9 were discarded because they had other diseases that can cause psychomotor retardation: 3 children with a polymalformative syndromes with mental retardation, 2 children with congenital hypothyroidism and 4 children with either Prader-Willi syndrome, hypoxic-ischemic encephalopathy grade III, intraventricular haemorrhage grade IV or etiologically unspecifi ed antenatal encephalopathy. Of the remaining 13 children in the control group, 9 were healthy, 4 had either duplicated pyelocalix system, concomitant strabismus, affective cyanotic spells or minor thalassemia. The risk group of 12 children was heterogeneously composed in terms of clinical course and time of infection (Table 1 ). In 6 children the infection was diagnosed as congenital (certain and probable) and 4 of them had a symptomatic infection with neurologic manifestations. CMV hepatitis was found in all symptomatic and concomitant infections: the children presented with hepatomegaly, elevated transaminases with/without laboratory evidence for impaired liver function.
Developmental delay at 3 years of age was found in only two children of the risk group (Table 1) , both with congenital CMV infection -symptomatic or concomitant. The child with developmental delay at three years of age (No. 1) had the most severe neonatal neurologic symptoms of all children in the risk group (Table 1) : the infant had also hepatitis, anaemia and fever. It was the only child exhibiting serological evidence for primary maternal CMV infection (CMV IgM-positive). The other child with developmental delay in the risk group (No. 8) was admitted to the Ward for problems in feeding and dehydration: the CMV infection was detected at the screening tests and was manifested only with mild hepatitis. This child was raised incorrectly by his mentally retarded mother.
We found no auditory defi cit in the risk group in the follow-up both by measuring their AEPs at 1 year of age and clinically at 3 years of age, in spite of the abnormal AEPs in the neonatal period of two of the children.
Greater morbidity rate was found only in two patients (Nos 7 and 8). One of these children suffered frequently from acute respiratory infections in his fi rst year only, while the other child, raised in worse welfare conditions, kept on having frequent infections in the following years.
Quantitative and qualitative analyses of the development milestones yielded no differences in the psychomotor development between the risk and control groups ( Table 2 ). There were no differences between the two groups with respect to the frequency of paroxysmal events (epileptic seizures, febrile convulsions, non-epileptic paroxysmal conditions), presence of sensory defi cits or morbidity rate.
DISCUSSION
The differentiation into risk and control groups in this study was based on evidence reported in literature that only infants with congenital or perinatal infection are at a risk of developing sequelae. 1 The obtained results can hold for clinical practices in hospitals with a similar level of competence like our hospital, and with similar indications for hospitalization.
The prognosis we found for the children of the risk group in this study is relatively good -we found no auditory deficiency in them, while a mild PMD delay was found only in 2 of the 12 children, one of which (case No. 8) could well be accounted for by the impact of some family and social etiological factors. The differences in the prognosis of children in the risk and control groups were not statistically signifi cant. The relatively favourable prognosis for the risk group can be explained by several factors: antiviral treatment of children at high risk of developing sequelae; no cases with severe congenital infection (cytomegalic inclusion disease); a likely presence in the risk group of cases with the more favourable in prognosis perinatal infection; the small number of children in the risk group making it impossible to fi nd any weak correlations.
The GCV treatment indications in this study refl ect the quest for balance between benefi t and * n; min-max = n -the number of children known to be able to perform the respective indicator; min -minimum age at beginning to do the parameter, max -the upper age limit for beginning to do the parameter. The choice of protocol for GCV treatment is based on the considerations that higher doses of GCV, a longer treatment and reduction of the viraemia improve the prognosis, but also increase the risk for adverse reactions. 6, 8, 10 GCV treatment protocol in this study was similar to those used by many European authors 8, 11 and alternative to the treatment with GCV (2х6 mg/kg daily for 6 weeks), used by some American researchers 7 and recommended in other publications 5 . The latter scheme has proven effi cient, but also with frequent adverse reactions and diffi culties in its implementation 1 
CONCLUSIONS
Hospitalized children with CMV infection, diagnosed in the fi rst 4 months of life and treated with GCV in the presence of neurological symptoms or severe clinical course of the disease, have a relatively favourable prognosis (in the absence of cases with cytomegalic inclusion disease). Delay in the PMD was established in one-sixth of those children.
